The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.

Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pietro Ferrara, Danilo Di Laura, Paolo A Cortesi, Lorenzo G Mantovani
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f75a38b6008d431e9c3941c8efc6109f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f75a38b6008d431e9c3941c8efc6109f
record_format	dspace
spelling	oai:doaj.org-article:f75a38b6008d431e9c3941c8efc6109f2021-12-02T20:15:26ZThe economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.1932-620310.1371/journal.pone.0254631https://doaj.org/article/f75a38b6008d431e9c3941c8efc6109f2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254631https://doaj.org/toc/1932-6203Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a clear picture of the economic impact of ASCVD secondary to hypercholesterolemia is lacking. This study aiming at conducting a systematic review of the current literature to assess the economic impact of familial hypercholesterolemia (FH), non-familial hypercholesterolemia (non-FH) or mixed dyslipidemia. A literature search was performed in Medline/PubMed and Embase database up to September 1st, 2020, exploring evidence published from 2010. The literature review was conducted in accordance with PRISMA guidelines. To be included the studies must be conducted on people who have been diagnosed with familial hypercholesterolemia, non-familial hypercholesterolemia or mixed dyslipidemia, and report data/information on costs attributable to these conditions and their sequelae. A total of 1260 studies were retrieved. After reading the titles and abstract, 103 studies were selected for full reading and eight met the criteria for inclusion. All but one studies were published in the American continent, with the majority conducted in US. An observational design with a prevalence approach were used and all estimated the economic burden of CVD. Direct cost estimates as annual average health expenditure on all population, ranging from $17 to $259 million. Few studies assessing the economic impact of hypercholesterolemia are available in the literature and new researches are needed to provide a more updated and reliable picture. Despite this scarceness of evidence, this review adds important data for future discussion on the knowledge of the economic impact of hypercholesterolemia and costs of care associated to this condition, with important implication for public health researches and novel therapies implementation.Pietro FerraraDanilo Di LauraPaolo A CortesiLorenzo G MantovaniPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254631 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Pietro Ferrara Danilo Di Laura Paolo A Cortesi Lorenzo G Mantovani The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
description	Hypercholesterolemia is a clinically relevant condition with an ascertained role in atherogenesis. In particular, its presence directly correlates to the risk of atherosclerotic cardiovascular disease (ASCVD). As known, cardiovascular diseases pose a significant economic burden worldwide; however, a clear picture of the economic impact of ASCVD secondary to hypercholesterolemia is lacking. This study aiming at conducting a systematic review of the current literature to assess the economic impact of familial hypercholesterolemia (FH), non-familial hypercholesterolemia (non-FH) or mixed dyslipidemia. A literature search was performed in Medline/PubMed and Embase database up to September 1st, 2020, exploring evidence published from 2010. The literature review was conducted in accordance with PRISMA guidelines. To be included the studies must be conducted on people who have been diagnosed with familial hypercholesterolemia, non-familial hypercholesterolemia or mixed dyslipidemia, and report data/information on costs attributable to these conditions and their sequelae. A total of 1260 studies were retrieved. After reading the titles and abstract, 103 studies were selected for full reading and eight met the criteria for inclusion. All but one studies were published in the American continent, with the majority conducted in US. An observational design with a prevalence approach were used and all estimated the economic burden of CVD. Direct cost estimates as annual average health expenditure on all population, ranging from $17 to $259 million. Few studies assessing the economic impact of hypercholesterolemia are available in the literature and new researches are needed to provide a more updated and reliable picture. Despite this scarceness of evidence, this review adds important data for future discussion on the knowledge of the economic impact of hypercholesterolemia and costs of care associated to this condition, with important implication for public health researches and novel therapies implementation.
format	article
author	Pietro Ferrara Danilo Di Laura Paolo A Cortesi Lorenzo G Mantovani
author_facet	Pietro Ferrara Danilo Di Laura Paolo A Cortesi Lorenzo G Mantovani
author_sort	Pietro Ferrara
title	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
title_short	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
title_full	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
title_fullStr	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
title_full_unstemmed	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.
title_sort	economic impact of hypercholesterolemia and mixed dyslipidemia: a systematic review of cost of illness studies.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/f75a38b6008d431e9c3941c8efc6109f
work_keys_str_mv	AT pietroferrara theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT danilodilaura theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT paoloacortesi theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT lorenzogmantovani theeconomicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT pietroferrara economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT danilodilaura economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT paoloacortesi economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies AT lorenzogmantovani economicimpactofhypercholesterolemiaandmixeddyslipidemiaasystematicreviewofcostofillnessstudies
_version_	1718374621482319872

The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies.

Ejemplares similares